secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001193125-26-065191
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Q4 net income $244.3M (full-year loss $80.0M); new PKU program; $500M Sixth Street credit facility
--------------------------------------------------------------------------------

- Q4 net income $244.3M ($2.33 diluted EPS); full-year net loss $80.0M ($0.81 per share).
- New liver-targeted program BEAM-304 for PKU; IND filing expected in 2026; targets two most prevalent PAH mutations.
- $500M senior secured credit facility with Sixth Street; $100M funded at close; additional draws tied to risto-cel milestones.
- Cash, cash equivalents and marketable securities $1.25B as of Dec 31, 2025; runway into mid-2029 with Sixth Street capital.
- Risto-cel BLA submission expected as early as year-end 2026; BEAM-302 FDA alignment on accelerated approval path.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000119312526065191/0001193125-26-065191-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000119312526065191/beam-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-065191

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer